INVIVYD INC (IVVD) Stock Price & Overview
NASDAQ:IVVD • US00534A1025
Current stock price
The current stock price of IVVD is 1.6 USD. Today IVVD is up by 0.63%. In the past month the price increased by 11.89%. In the past year, price increased by 146.19%.
IVVD Key Statistics
- Market Cap
- 452.48M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.36
- Dividend Yield
- N/A
IVVD Stock Performance
IVVD Stock Chart
IVVD Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to IVVD. When comparing the yearly performance of all stocks, IVVD is one of the better performing stocks in the market, outperforming 91.9% of all stocks.
IVVD Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to IVVD. IVVD has a great financial health rating, but its profitability evaluates not so good.
IVVD Earnings
On January 8, 2026 IVVD reported an EPS of -0.04 and a revenue of 17.21M. The company beat EPS expectations (55.18% surprise) and beat revenue expectations (18.59% surprise).
IVVD Forecast & Estimates
10 analysts have analysed IVVD and the average price target is 8.16 USD. This implies a price increase of 410% is expected in the next year compared to the current price of 1.6.
For the next year, analysts expect an EPS growth of 54.67% and a revenue growth 67.81% for IVVD
IVVD Groups
Sector & Classification
IVVD Financial Highlights
Over the last trailing twelve months IVVD reported a non-GAAP Earnings per Share(EPS) of -0.36. The EPS increased by 75.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.96% | ||
| ROE | -21.73% | ||
| Debt/Equity | 0 |
IVVD Ownership
IVVD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 362.808B | ||
| AMGN | AMGEN INC | 15.15 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.79 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.65 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IVVD
Company Profile
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in New Haven, Connecticut and currently employs 122 full-time employees. The company went IPO on 2021-08-06. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The firm delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The firm also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
Company Info
IPO: 2021-08-06
INVIVYD INC
209 Church Street
New Haven CONNECTICUT US
Employees: 122
Phone: 17818190080
INVIVYD INC / IVVD FAQ
What does IVVD do?
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in New Haven, Connecticut and currently employs 122 full-time employees. The company went IPO on 2021-08-06. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The firm delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The firm also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
What is the current price of IVVD stock?
The current stock price of IVVD is 1.6 USD. The price increased by 0.63% in the last trading session.
What is the dividend status of INVIVYD INC?
IVVD does not pay a dividend.
What is the ChartMill rating of INVIVYD INC stock?
IVVD has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Is INVIVYD INC (IVVD) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IVVD.
Can you provide the growth outlook for INVIVYD INC?
The Revenue of INVIVYD INC (IVVD) is expected to grow by 67.81% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.